|
Jun 25
|
Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls
|
|
Jun 25
|
Novo Nordisk Wins Weight-Loss Drug Approval in China; Plans $4.1 Billion US Facility
|
|
Jun 25
|
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
|
|
Jun 25
|
Dow Jones Falls, But Nvidia Rebounds, Novo Nordisk Clears Key Level; Tesla Cybertruck Recall
|
|
Jun 25
|
Novo Nordisk Rises as Wegovy Is Approved in China
|
|
Jun 17
|
New Weight-Loss Drugs and Devices Are Coming This Week
|
|
Jun 17
|
Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs
|
|
Jun 17
|
Could Structure Therapeutics Become the Next Novo Nordisk?
|
|
Jun 17
|
Ozempic is 1,300% more expensive in the U.S. vs the U.K.—so the boss of Novo Nordisk is being hauled in front of Bernie Sanders to explain why
|
|
Jun 15
|
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
|
|
Jun 14
|
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
|
|
Jun 14
|
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
|
|
Jun 14
|
Eli Lilly unveils new manufacturing plant for GLP-1 pens
|
|
Jun 14
|
IBD Sector Leaders: Top Picks To Watch Include Nvidia Stock, Ozempic Maker Novo Nordisk
|
|
Jun 14
|
Few IBD 50 Stocks In Buy Zones; Netflix Is One
|
|
Jun 14
|
Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research
|
|
Jun 14
|
Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market
|
|
Jun 14
|
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
|
|
Jun 14
|
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
|
|
Jun 12
|
Market Chatter: Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan
|